BACKGROUND: Elevated levels of midrange proadrenomedullin (MR-proADM) are associated with worse outcome in different diseases, including COPD. The association of stable-state MR-proADM with severe acute exacerbations of COPD (AECOPDs) requiring hospitalization, or with community-acquired pneumonia (CAP) in patients with COPD, has not been studied yet. The aim of this study was to evaluate the association of stable-state MR-proADM with severe AECOPD and CAP in patients with COPD.
COPD is a complex and heterogeneous disease accompanied with increased morbidity and mortality. 1, 2 Underlying chronic and systemic inflammation play an important role in the pathophysiology of COPD, the progression of COPD, and the associated comorbidities of COPD. [3] [4] [5] [6] It is estimated that COPD is the third leading cause of death worldwide. 7 COPD is characterized by acute exacerbations of COPD (AECOPDs), which can accelerate the already existing gradual decline in lung function and increase the risk of death. 8, 9 Furthermore, AECOPDs are associated with increased risk of hospitalization, lower quality of life, and increased health-care costs. 8, 10 Effective therapy or interventions to prevent this morbidity and mortality include for instance inhalation medication, smoking cessation, supplemental oxygen therapy, pulmonary rehabilitation, and lung transplantation.
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For adequate prognostication, we need more insight in the pathophysiology of this complex and heterogeneous disease. Different biomarkers have been evaluated for this purpose. One of these biomarkers is midrange roadrenomedullin (MR-proADM), the biologically inactive midregional fragment of the adrenomedullin (ADM) prohormone. 12 The pluripotent regulatory peptide ADM is widely expressed throughout the body and acts as both a hormone and a cytokine. 13 ADM can be upregulated by hypoxia, inflammation, bacterial products, and shear stress and with its widespread expression in pulmonary tissue, among which endothelial cells (including type 2 pneumocytes), smooth muscle cells, neurons and immune cells, elevated ADM levels can often be seen in (end stage) pulmonary diseases such as COPD and communityacquired pneumonia (CAP). [14] [15] [16] ADM potentially has comprehensive effects such as vasodilatory, diuretic, anti-inflammatory, and antimicrobial. In preclinical and animal models, ADM has been shown to reduce hypoxic pulmonary vascular remodeling, inhibit bronchoconstriction, and downregulate proinflammatory factors. 17 Therefore, ADM has compensatory and regulatory capacities to achieve homeostasis.
Despite these beneficial and protective effects, the upregulation of ADM should be interpreted as a need for these compensatory/regulatory effects because of the underlying severity of the illness at that moment. 15 Therefore, although having these beneficial and protective effects, elevated MR-proADM is associated with worse clinical outcome in different diseases such as sepsis, heart failure, myocardial infarction, and CAP. 17, 18 Not surprisingly, in COPD, elevated MR-proADM is associated with worse outcome as well, and MRproADM has even been evaluated as being an independent predictor for survival in COPD. 19, 20 CAP and severe AECOPD resulting in hospitalization are among the most important factors contributing to the morbidity in COPD and are associated with a high burden of disease and low quality of life. 21 Although elevated MR-proADM measured during CAP in the general population and during an exacerbation in COPD are both associated with worse outcome, it would be interesting to study whether already elevated levels in patients with stable-state COPD could be a marker for the approach of this morbidity. 18, 22 The association of stable-state MR-proADM with the occurrence of CAP and AECOPD has however never been studied until now. 
Outcomes
The outcome parameters were time until first hospitalization for an AECOPD and time until first CAP. For time until first CAP, only data from patients included in the COMIC study were available. AECOPD was defined as an acute negative change from baseline, reported by the patient, in dyspnea and/or sputum volume and/or colour of sputum (yellowish or greenish sputum) and/or cough, which may warrant additional treatment of prednisolone with or without antibiotics by a physician in a patient with underlying COPD. Pneumonia was defined as an acute respiratory tract illness associated with radiographic shadowing on a chest radiograph consistent with infection which was neither preexisting nor of any other known cause. 23 All radiographs were double read by a radiologist and a chest physician. In case of doubtful shadows in the report, the radiograph was presented to another chest physician for final judgment.
MR-proADM
Plasma samples of MR-proADM were obtained at stable state, and levels were measured with an automated sandwich immunoassay using a time-resolved amplified cryptate emission technology. 24 Stable state is defined as the moment in which no exacerbation occurred and no prednisolone or antibiotics were used for a minimum of 4 weeks before the blood sample was taken. MR-proADM level was dichotomized as high ($ 0.87 nmol/L) or low level (< 0.87 nmol/L), as defined in an earlier study with the pooled cohorts. 19 
Statistical Analyses
Continuous variables are expressed as mean AE SD or median (interquartile range), and categorical variables are presented as counts (percentages). Time from inclusion to event (first hospitalization for a severe AECOPD or first CAP) was analyzed by Kaplan-Meier survival curves and compared between patients with COPD with high ($ 0.87 nmol/L) or low (< 0.87 nmol/L) levels of MR-proADM with log-rank tests. Univariate and multivariate Cox proportional hazard regression models were used to establish the association of MR-proADM with time until first hospitalization for an AECOPD and time until first CAP. First, we studied in univariate analyses the association between MR-proADM and potential confounders within the baseline characteristics such as lung function parameters, previous AECOPD in the year before inclusion, Global Initiative for Chronic Obstructive Lung Disease stage, BMI, comorbidity, and sex. Next, we studied in multivariate Cox proportional hazard regression models the association between the outcome parameters (time until first hospitalization for an AECOPD or time until first CAP) on the one hand and MR-proADM level on the other hand, and added all confounders (ie, variables that were associated with MR-proADM and the outcome parameter of the specific models with a corresponding P value < .10). We started the multivariate model with all confounders. Variables with the highest P value were eliminated step by step until the fit of the model decreased significantly, based on À2 log likelihood. All tests were two-sided, and P ¼ .05 was considered statistically significant. Data were analyzed using SPSS version 22 (SPSS Inc.)
Results

Baseline Characteristics
In 1,285 out of 1,433 patients from both studies, MR-proADM was measured in stable state, and these patients were used for the analyses. The baseline characteristics of these patients are displayed in Table 1 , stratified for both studies. Median follow-up times of the COMIC and PROMISE-COPD studies were, respectively, 915 (range, 824-1068) and 725 (range, 421-764) days. There were 321 (25%) patients defined as having a high level of stable-state MR-proADM. The cumulative proportion of patients with at least one severe AECOPD in the pooled analysis and at least one CAP in the COMIC study after 1, 2, and 3 years is displayed in Tables 2 and 3 , respectively, stratified for low and high level of stable-state MR-proADM.
Time Until First Hospitalization for an AECOPD
In the pooled analysis, patients with COPD with high-level stable-state MR-proADM (n ¼ 321) had a significantly higher risk for a severe AECOPD compared with those with low-level MR-proADM (n ¼ 964) (Fig 1) (log-rank: P < .001), with a hazard ratio (HR) of 1.56 (95% CI, 1.24-1.98) in univariate analysis. In the multivariate Cox regression analysis, patients with high-level stable-state MR-proADM, corrected for the confounders FEV 1 (liters), BMI, modified Medical Research Council Scale dyspnea grade, heart failure, diabetes mellitus, and previous AECOPDs, still had a significantly higher risk for a severe AECOPD with a corrected HR of 1.30 (95% CI, 1.01-1.68). For more details see Table 4 .
Time Until First CAP
In the COMIC study, patients with COPD with high-level stable-state MR-proADM (n ¼ 197) had a significantly higher risk for CAP compared with patients with COPD with low-level MR-proADM (n ¼ 474) (Fig 2) (log-rank: P ¼ .003), with an HR of 1.93 (95% CI, 1.24-3.01) in univariate analysis. However, corrected for age, FEV 1 (liters), and previous AECOPDs in multivariate Cox regression analysis, this association was no longer significant (corrected HR, 1.10; 95% CI, 0.68-1.80). For more details see Table 4 .
Discussion
In our pooled analysis of two large European COPD cohort studies MR-proADM, measured in stable state, was shown to be an important biomarker for the occurrence of a future severe AECOPD. A high level of MR-proADM, measured in stable state, was associated with a 30% increased risk of a severe AECOPD when corrected for potential confounders such as lung function, previous AECOPD, age, and comorbid status. With 25% of the patients having a high stable-state MR-proADM level and with 34% (cumulative proportion) of the patients having at least one severe AECOPD during the 3 years of follow-up, our results are not only significant but are clinically relevant as well.
How can we explain this finding? It is known that ADM secretion is stimulated by tumor necrosis factor-alpha, chestjournal.org IL-beta, and lipopolysaccharide. 17 Besides, hypoxia leads to ADM upregulation through the hypoxia inducible factor-1 pathway. 25 These are all factors accompanying AECOPD and CAP, either causal or as a result. Elevated ADM in stable state therefore probably represents a higher demand on the regulatory mechanisms ascribed to ADM. This higher demand is provoked by a possible higher continuous, or an at that moment active underlying (systemic) inflammation, hypoxia, bacterial exposition, or colonization and cardiovascular instability/comorbidity contrary to patients with nonelevated ADM levels. All these processes are associated with disease progression in COPD and promote development of comorbidity such as atherosclerosis and muscle wasting and osteopenia. 26 Therefore, in a way, stable state is probably not that stable in patients with COPD with elevated MR-proADM.
The higher ADM, measured in stable state, could implicate that the patient is either at risk for impending disease instability or is already somewhat unstable (although they did not receive any prednisolone or antibiotics for the last 4 weeks), which in the end could lead to a negative outcome such as a severe exacerbation or infectious disease.
In our study, MR-proADM was not associated with CAP. In the general population, MR-proADM measured in patients with CAP was associated with disease severity and was an independent predictor for clinical outcome including mortality and it had additive prognostic value combined with the Pneumonia Severity Index and CURB-65. 24, [27] [28] [29] As mentioned, there is a rationale that high levels of stable-state MR-proADM could be associated with CAP in patients with COPD. Indeed, there was a positive association between MR-proADM and outcome; however, it was not significant after adjustment for age and FEV 1 . It cannot be excluded that the smaller sample size could be responsible for this finding (ie, beta error).
Evidence has accumulated that MR-proADM is associated with morbidity and mortality at different time points during the course of COPD. In stable state, high MR-proADM level is associated with severe AECOPD, exertional hypoxemia, 25 and mortality. 20 During exacerbation, high MR-proADM level predicts length of hospital stay and mortality, 17 and elevated MR-proADM at hospital discharge predicts survival as well. 30 It would be interesting to know how the association and predictive value of MR-proADM with morbidity and mortality behaves when serial longitudinal measurements within one patient are made during the course of the disease. Are changes in the MR-proADM level followed by changes in disease activity? And in which time frame? And does treatment (pharmacologic and/or nonpharmacologic) of COPD influence MR-proADM levels followed by disease optimization? Future studies have to address these topics.
There are different causes for exacerbations. 10 It is debatable whether one biomarker would be capable to encompass the whole complexity of exacerbations. Different biomarkers are described as associated with exacerbations (with or without hospitalization). 31 In a recent large-scale biomarker panel study using two large and well-characterized cohorts by Keene et al, 32 many of these biomarkers were no longer associated with or predictive of exacerbations, and their additive value with known predictive clinical parameters was limited as well.
The role for these biomarkers in COPD has therefore become uncertain. To our knowledge, stable-state MR-proADM has never been evaluated with morbidity Table 2 legend for expansion of abbreviation.
1,000 800 600 log-rank: P < . in COPD until now. The independent predictive capability of MR-proADM as an independent predictor for AECOPD in patients with COPD still has to be established in a prediction model, in which all other known predictors are taken into account. In this way, the additive prognostic value of MR-proADM to other known predictors can be studied.
The cutoff level of MR-proADM used in this study was based on an earlier study. 19 However, that was a study with mortality as the end point. To establish whether the value of 0.87 nmol/L was the ideal cutoff level for morbidity as well, we performed additional analyses with different validated cutoff levels of MR-proADM used in a recent validation study. 33 The different cutoff levels did not result in a stronger association (data not shown); therefore, the cutoff value of 0.87 nmol/L seems to be reasonable for morbidity as well.
This study has some limitations. First, the patients in the PROMISE-COPD study had a slightly worse lung function, were more often current smokers, and had more comorbidity than the patients in the COMIC study. Conversely, a higher proportion of the patients included in the COMIC study were included during an AECOPD, a fact known to be an important predictor for a new exacerbation. 34 Therefore, a limitation of the study is that the patients included may have more severe COPD and are mainly controlled and treated in secondary care. Therefore, the results of this study cannot automatically be extrapolated to patients with mild COPD controlled in primary care; however, pathophysiologically, there is no reason why MR-proADM should act different in mild COPD.
Second, the study lacks information about supplemental oxygen use, gastroesophageal reflux disease, previous pulmonary rehabilitation status, and other (inhalation) medication use other than the known inhaled corticosteroid used by 80% of the patients.
The strength of this study however includes its large sample size of a well-characterized multicenter cohort from several European countries. The various established and validly assessed covariates made it possible to determine the association of stable-state MR-proADM with morbidity. Moreover, this study design with the pooled analysis potentiates the generalizability of stable-state MR-proADM being an important biomarker for future severe AECOPDs.
In conclusion, plasma MR-proADM measured at stable state in patients with COPD is significantly associated with future severe AECOPDs but not CAP in a large, pooled European COPD cohort. Future studies should address the additive value of stable-state MR-proADM as an independent predictor with other known (clinical) predictors for severe AECOPDs. 
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